May 27, 2008 -- 3SBio, Inc. (NSDQ: SSRX) has signed a development-commercialization deal with AMAG Pharmaceuticals, Inc. (NSDQ: AMAG) to obtain SFDA approval and then market ferumoxytol, an intravenous iron replacement therapeutic agent being developed to treat iron deficiency anemia in chronic kidney disease (CKD) patients. 3SBio paid $1 million upfront and will make milestone payments as ferumoxytol achieves regulatory goals for chronic kidney disease and other indications. More details...
